News|Videos|November 6, 2023
Factors in Frontline Treatment Decision Making for Endometrial Cancer
Author(s)Ritu Salani, MD, Bhavana Pothuri, MD
Key factors influencing frontline treatment choices in endometrial cancer, including biomarker status, comorbidities, guidelines, and patient preferences, with a focus on the evolving landscape of therapies.
Advertisement
Episodes in this series
Advertisement
Related to this article
Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
Ris-Rez Extends Median OS to 18.5 Months vs Topotecan in Relapsed SCLC
2
Tam-Peli Reduces Risk of Death by 54% vs Topotecan in Relapsed SCLC
3
Iza-Bren Elicits 33% ORR, 6.9-Month PFS in Post-Osimertinib EGFR-Mutated NSCLC
4
Dr Liu on Building on the ADRIATIC Regimen in Limited-Stage Small Cell Lung Cancer
5